Sodium Thiosulfate: A Century-Old Antidote Quietly Reinventing Itself
The catch? Most of those newer roles have only been demonstrated in animal models and lab studies. What sodium thiosulfate (STS) can reliably do in humans right now, and what it might do in the future, are two very different conversations. Both are worth having.
Three Things It Already Does Well
STS has a short list of clinically validated uses, but each one is remarkably distinct from the others.
| Indication | How STS Works Here | Current Status |
|---|---|---|
| Cyanide poisoning | Donates sulfur so the body converts cyanide to less toxic thiocyanate | WHO essential medicine; standard antidote |
| Calciphylaxis in dialysis patients | Chelates (binds) calcium, counteracting dangerous tissue calcification | Off-label but widely used in end-stage renal disease |
| Cisplatin-related hearing loss in children | Inactivates residual cisplatin and boosts glutathione (a key internal antioxidant) | FDA-approved as Pedmark; reduced hearing loss in randomized controlled trials |
That range, from acute poisoning to chemotherapy side effects to a rare calcification disorder, hints at why researchers think STS has untapped potential. A drug that chelates metals, boosts antioxidant defenses, and interacts with hydrogen sulfide pathways is doing several mechanistically different things at once.
Five Mechanisms, One Small Molecule
What makes STS unusual is the sheer number of biological levers it appears to pull. Based on the available research, five stand out.
Direct antioxidant activity. STS quenches reactive oxygen species (ROS) on contact and helps preserve the body's own antioxidant enzymes, including glutathione and superoxide dismutase, in liver and kidney models.
Anti-inflammatory and inflammasome suppression. It reduces inflammatory cytokines and blocks activation of the NLRP3 inflammasome, a molecular alarm system involved in a wide range of chronic diseases. This has been shown in both skin and systemic inflammation models.
Metal and calcium chelation. STS binds calcium and transition metals like iron and copper. That property is directly relevant to calciphylaxis, kidney stones, and even the metal-laden particles in air pollution (PM₂.₅).
Hydrogen sulfide signaling. STS acts as a metabolite, donor, or carrier of H₂S, a gaseous signaling molecule the body naturally produces. Through this pathway, it increases polysulfides and something called protein persulfidation, influencing blood vessel relaxation, mitochondrial function, and cell survival pathways including caspase-3 (a key enzyme in programmed cell death).
Mitochondrial protection. In models of liver ischemia-reperfusion injury, heart damage, and PM₂.₅ cardiotoxicity, STS preserved mitochondrial structure, energy production, and the cleanup process called mitophagy.
These mechanisms overlap and reinforce each other, which is partly why the same compound works in such different diseases.
Where the Excitement Is Building (And Where the Evidence Isn't)
The emerging applications of STS read like a wish list of modern medicine's hardest problems. But "emerging" is doing heavy lifting in that sentence.
Heart and kidney protection. In rats with nitric oxide deficiency (a model for hypertension), STS improved blood pressure, cardiac remodeling, kidney function, and oxygen utilization. In some of these models, its effects were comparable to ACE inhibitors, a major class of blood pressure medication. That's genuinely interesting, but it's animal data.
Ischemia-reperfusion injury. When blood flow is cut off and then restored (during surgery, heart attacks, or organ transplants), the returning oxygen can paradoxically cause severe tissue damage. STS has been protective in liver and heart models of this injury. However, some trauma and hemorrhage models showed neutral or even mixed results. The research makes clear that benefit here is context-dependent: the organ, the timing, and the severity all seem to matter.
Alzheimer's disease. Narrative reviews have proposed STS as a multi-target candidate for late-onset Alzheimer's, based on its antioxidant, anti-inflammatory, and H₂S-related signaling properties. There is also evidence that thiosulfate mediates neuroprotection from H₂S in cerebral ischemia models. But clinical data in Alzheimer's patients simply does not exist yet. This is hypothesis-stage work.
Atopic dermatitis. Both clinical observations and mouse studies suggest STS can improve skin lesions and itching, with reduced Th2 cytokines (immune signals that drive allergic inflammation) and lower inflammasome activation. This is further along than the Alzheimer's work but still early.
The Safety Profile Is Forgiving, Not Flawless
STS is generally well tolerated, which is part of why it's been used for over a century. But "generally" leaves room for real caveats.
Known side effects include:
- Transient hypernatremia (elevated sodium levels)
- Metabolic acidosis
- GI upset (nausea, vomiting)
- Rare allergic reactions
High-dose intravenous use in patients with kidney failure requires careful monitoring. And in some animal models, STS provided no benefit or even caused possible pulmonary impairment. The research frames this clearly: the benefit of STS is disease-specific and timing-specific. It is not a universal protectant, and assuming it will help in every inflammatory or oxidative scenario would be a mistake.
Old Drug, New Identity
The trajectory of sodium thiosulfate research over the last decade tells a clear story. It has shifted from a niche antidote toward a compound studied for its antioxidant, mitochondrial, and signaling properties across cardiovascular, renal, neurologic, and dermatologic disease.
But the honest picture is this: STS has three well-supported human applications (cyanide poisoning, calciphylaxis, cisplatin ototoxicity) and a growing list of preclinical possibilities that have not yet been tested rigorously in people. The mechanisms are plausible and, in some cases, genuinely compelling. The human evidence for newer uses is not there yet.
If you're a dialysis patient dealing with calciphylaxis, or a parent whose child faces cisplatin treatment, STS is already a proven tool worth discussing with your medical team. If you're drawn to the cardiovascular or neuroprotective research, the honest move is to watch this space closely rather than act on animal data. The molecule is real. The promise is real. The proof, for most of the exciting new applications, is still coming.
